Meta-analysis of renin-angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 3-4, 2011, Pages 368-375

  Meune, Christophe ^a   Wahbi, Karim ^b   Duboc, Denis ^a   Weber, Simon ^a  

^a Université Paris Descartes ^*  (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

angiotensin converting enzyme inhibitor; angiotensin II receptor antagonist; heart failure; meta analysis; preserved ejection fraction; ventricular function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL;

CONFERENCE PAPER; DRUG EFFECT; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HOSPITALIZATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 80051495845     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410391667     Document Type: Conference Paper

References (33)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 ; 355 (3). 251-259 (Pubitemid 44079340)
2. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003 ; 289 (2). 194-202 (Pubitemid 36068707)
3. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995 ; 26 (7). 1565-1574
4. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000 ; 101 (17). 2118-2121 (Pubitemid 30233178)
5. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. Circulation. 2001 ; 104 (7). 779-782 (Pubitemid 32762675)
6. Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis. 2005 ; 47 (6). 357-366 (Pubitemid 41188342)
7. Korprowski A, Gruchala M, Rynkiewicz A. Management of left ventricular diastolic heart failure: is it only blood pressure control?. Curr Opin Cardiol. 2009 ; 24 (2). 161-166
8. Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M. Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol. 2008 ; 101 (5). 639-644 (Pubitemid 351625089)
9. Johnson D, Jin Y, Quan H, Cujec B. Beta-blockers and angiotensin- converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol. 2003 ; 48 (2). 1438-445 (Pubitemid 37267287)
10. Shamagian LG, Roman AV, Ramos PM, Velosos PR, Dieguez MAB, Gonzalez-Juanatey JR. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail. 2006 ; 12 (2). 128-133 (Pubitemid 43340155)
11. Philbin EF, Rocco TA, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med. 2000 ; 109 (8). 605-613
12. Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J. 1997 ; 134 (2 pt 1). 188-195 (Pubitemid 27406679)
13. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006 ; 27 (19). 2338-2345 (Pubitemid 44453578)
14. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 ; 359: 2456-2467
15. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 ; 362 (9386). 777-781 (Pubitemid 37093918)
16. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ. 2000 ; 321 (7255). 215-218 (Pubitemid 30459560)
17. Banerjee P, Clark AL, Nikitin N, Cleland JG. Diastolic heart failure. Paroxysmal or chronic?. Eur J Heart Fail. 2004 ; 6 (4). 427-431 (Pubitemid 38746585)
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1984 ; 50: 1088-1101
19. Yip GWK, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan, and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008 ; 94 (5). 573-580 (Pubitemid 351580128)
20. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002 ; 105 (11). 1387-1393 (Pubitemid 34260433)
21. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005 ; 11 (3). 177-187 (Pubitemid 40462419)
22. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003 ; 107 (5). 714-720 (Pubitemid 36222599)
23. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function?. Circulation. 2003 ; 107 (5). 656-658 (Pubitemid 36222586)
24. Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahlström U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004 ; 6 (4). 453-461 (Pubitemid 38746589)
25. Persson H, Lonn E, Edner M, et al. Investigators of the CHARM Echocardiographic substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol. 2007 ; 49 (6). 687-694 (Pubitemid 46205045)
26. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation. 2002 ; 105 (10). 1195-1201 (Pubitemid 34225820)
27. Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis. 2005 ; 47 (6). 357-366 (Pubitemid 41188342)
28. O'Meara E, Clayton T, McEntegart MB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure. Results of the Candesartan in Heart Failure: Assessment of reduction in Mortality and Morbidity (CHARM program). Circulation. 2007 ; 115 (24). 3111-20 (Pubitemid 46956500)
29. Cohen-Solal A, McMurray JJV, Swedberg K, et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity programme. Eur Heart J. 2008 ; 29 (24). 3022-8
30. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 ; 355 (3). 260-269 (Pubitemid 44088349)
31. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007 ; 50 (8). 768-777 (Pubitemid 47243795)
32. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail. 2009 ; 11 (9). 855-862
33. Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010 ; 16 (3). 260-267